Trial · NCT02514044
Dextroamphetamine and tDCS to Improve the Fluency
NCT02514044, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2018-08-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dextroamphetamine and tDCS to Improve the Fluency. Trials, record NCT02514044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02514044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dextroamphetamine and tDCS to Improve the Fluency
- NCT number
- NCT02514044
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Stroke
- Interventions
- Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS
- First posted
- 2015-08-03
- Last updated
- 2018-08-03
- Results first posted
- 2018-08-03
- Limitations and caveats
- The safety phase of the study was completed; however, the efficacy phase was not started.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Language Quotient as Assessed by the Western Aphasia Battery | immediately before the treatment, immediately after the treatment | The score on the Language Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported. |
| Primary | Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery | immediately before the treatment, immediately after the treatment | The score on the Aphasia Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported. |
| Secondary | Boston Diagnostic Aphasia Examination | Baseline,2 weeks | |
| Secondary | Boston Diagnostic Aphasia Examination | Baseline,2 months | |
| Secondary | Percent Change in Blood Pressure | immediately before the treatment, after after the treatment | Non-invasive BP measurements performed by a clinician before and after each experiment. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Language Quotient as Assessed by the Western Aphasia Battery | immediately before the treatment, immediately after the treatment | percent change in language quotient | MEAN | |
| PRIMARY | Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery | immediately before the treatment, immediately after the treatment | percent change in aphasia quotient | MEAN | |
| SECONDARY | Boston Diagnostic Aphasia Examination | Baseline,2 weeks | Data not collected. | ||
| SECONDARY | Boston Diagnostic Aphasia Examination | Baseline,2 months | Data not collected. | ||
| SECONDARY | Percent Change in Blood Pressure | immediately before the treatment, after after the treatment | percent change in blood pressure | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Language Quotient as Assessed by the Western Aphasia Battery | Dexedrine+tDCS+Speech Therapy | 11.02 | 95% Confidence Interval 3.22 to 18.81 | percent change in language quotient | |
| Percent Change in Language Quotient as Assessed by the Western Aphasia Battery | Placebo+tDCS+Speech Therapy | -4.2 | 95% Confidence Interval -10.57 to 2.26 | percent change in language quotient | |
| Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery | Dexedrine+tDCS+Speech Therapy | 7.9 | 95% Confidence Interval 1.49 to 14.31 | percent change in aphasia quotient | |
| Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery | Placebo+tDCS+Speech Therapy | -.02 | 95% Confidence Interval -7.63 to 7.19 | percent change in aphasia quotient | |
| Percent Change in Blood Pressure | Dexedrine+tDCS+Speech Therapy | Systolic blood pressure | 10 | Standard Deviation 3 | percent change in blood pressure |
| Percent Change in Blood Pressure | Placebo+tDCS+Speech Therapy | Systolic blood pressure | 4 | Standard Deviation 1 | percent change in blood pressure |
| Percent Change in Blood Pressure | Dexedrine+tDCS+Speech Therapy | Diastolic blood pressure | 11 | Standard Deviation 5 | percent change in blood pressure |
| Percent Change in Blood Pressure | Placebo+tDCS+Speech Therapy | Diastolic blood pressure | 5 | Standard Deviation 2 | percent change in blood pressure |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dexedrine+tDCS+Speech Therapy (1 Day) | STARTED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Dexedrine+tDCS+Speech Therapy (1 Day) | COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Dexedrine+tDCS+Speech Therapy (1 Day) | NOT COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 0 | |
| Washout (1 Week) | STARTED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Washout (1 Week) | COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Washout (1 Week) | NOT COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 0 | |
| Placebo+tDCS+Speech Therapy (1 Day) | STARTED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Placebo+tDCS+Speech Therapy (1 Day) | COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 10 | |
| Placebo+tDCS+Speech Therapy (1 Day) | NOT COMPLETED | Dexedrine+tDCS+Speech Therapy, Then Placebo+tDCS+Speech Therap | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Non-significant skin redness and tingling | Skin and subcutaneous tissue disorders | D-AMP+tDCS+Speech Therapy | 9 | 10 | 9 |
| other | Non-significant skin redness and tingling | Skin and subcutaneous tissue disorders | Placebo+tDCS+Speech Therapy | 9 | 10 | 9 |
| other | Mild Headache | Nervous system disorders | D-AMP+tDCS+Speech Therapy | 2 | 10 | 2 |
| other | Mild Headache | Nervous system disorders | Placebo+tDCS+Speech Therapy | 2 | 10 | 2 |
| other | Mild Insomnia | Nervous system disorders | D-AMP+tDCS+Speech Therapy | 1 | 10 | 1 |
| other | Mild Insomnia | Nervous system disorders | Placebo+tDCS+Speech Therapy | 0 | 10 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | D-AMP+tDCS+Speech Therapy | 0 | 10 |
| Total, all-cause mortality | Placebo+tDCS+Speech Therapy | 0 | 10 |
| Total, other adverse events | D-AMP+tDCS+Speech Therapy | 9 | 10 |
| Total, other adverse events | Placebo+tDCS+Speech Therapy | 9 | 10 |
| Total, serious adverse events | D-AMP+tDCS+Speech Therapy | 0 | 10 |
| Total, serious adverse events | Placebo+tDCS+Speech Therapy | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| D-AMP+tDCS+Speech Therapy vs Placebo+tDCS+Speech Therapy: deaths from any cause | Trial comparisons |
| D-AMP+tDCS+Speech Therapy vs Placebo+tDCS+Speech Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02514044
GET https://conductscience.org/api/trials/v1/NCT02514044/registered